BAIT
HSPB1
CMT2F, HEL-S-102, HMN2B, HS.76067, HSP27, HSP28, Hsp25, SRP27
heat shock 27kDa protein 1
GO Process (21)
GO Function (7)
GO Component (8)
Gene Ontology Biological Process
- RNA metabolic process [TAS]
- cellular component movement [TAS]
- cellular response to vascular endothelial growth factor stimulus [IMP]
- gene expression [TAS]
- intracellular signal transduction [IMP]
- mRNA metabolic process [TAS]
- negative regulation of apoptotic process [TAS]
- negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [ISS]
- negative regulation of protein kinase activity [ISS]
- platelet aggregation [IMP]
- positive regulation of angiogenesis [IMP]
- positive regulation of blood vessel endothelial cell migration [IMP]
- positive regulation of endothelial cell chemotaxis [IMP]
- positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway [IMP]
- positive regulation of interleukin-1 beta production [ISS]
- positive regulation of tumor necrosis factor biosynthetic process [ISS]
- regulation of I-kappaB kinase/NF-kappaB signaling [ISS]
- regulation of translational initiation [TAS]
- response to unfolded protein [NAS]
- response to virus [IEP]
- retina homeostasis [IEP]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
SBF1
CMT4B3, DENND7A, MTMR5, C22:RP4-579N16.2
SET binding factor 1
GO Process (2)
GO Function (2)
GO Component (1)
Gene Ontology Biological Process
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
Two-hybrid
Bait protein expressed as a DNA binding domain (DBD) fusion and prey expressed as a transcriptional activation domain (TAD) fusion and interaction measured by reporter gene activation.
Publication
The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.
Previously, we identified the stress-induced chaperone, Hsp27, as highly overexpressed in castration-resistant prostate cancer and developed an Hsp27 inhibitor (OGX-427) currently tested in phase I/II clinical trials as a chemosensitizing agent in different cancers. To better understand the Hsp27 poorly-defined cytoprotective functions in cancers and increase the OGX-427 pharmacological safety, we established the Hsp27-protein interaction network using a yeast two-hybrid ... [more]
Mol. Cell Proteomics Dec. 01, 2014; 13(12);3585-601 [Pubmed: 25277244]
Throughput
- High Throughput
Curated By
- BioGRID